Verastem Oncology Reports First Quarter 2019 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Wall St rises on AI gains as oil slides, Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips briefly below $100 on Saudi exports, hopes of US-Iran diplomacy
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Qatar Investment Authority targets $20B partnership with JPMorgan - Bloomberg
- AMD stock jumps as chip rally builds ahead of summit
Verastem (VSTM) Misses Q1 EPS by 5c, Revenues Miss; FY19 Revenue Guidance Below Consensus
May 9, 2019 4:47 PM EDTVerastem (NASDAQ: VSTM) reported Q1 EPS of ($0.52), $0.05 worse than the analyst estimate of ($0.47). Revenue for the quarter came in at $1.67 million versus the consensus estimate of $2.91 million.
We are now into the second full quarter of the COPIKTRA launch and sales were up approximately 38% compared to the prior quarter, said Robert Forrester, President and Chief... More
